13990-07-3

Basic information

• Product Name: (3,5-dibromo-4-hydroxy-phenyl)-pyruvic acid
• Synonyms: (3,5-dibromo-4-hydroxy-phenyl)-pyruvic acid
• CAS NO: 13990-07-3
• Molecular Weight: 337.952
• Mol File: 13990-07-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (3,5-dibromo-4-hydroxy-phenyl)-pyruvic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3,5-dibromo-4-hydroxy-phenyl)-pyruvic acid(13990-07-3)
• EPA Substance Registry System: (3,5-dibromo-4-hydroxy-phenyl)-pyruvic acid(13990-07-3)

Safety Data

• Hazardous Substances Data: 13990-07-3(Hazardous Substances Data)

Upstream product

• 1389250-13-8 C₁₁H₉Br₂NO₃ 
• 2973-77-5 3,5-dibromo-4-hydroxybenzaldehyde 
• 91805-72-0 2,6-dibromo-4-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)phenyl acetate 
• 866087-52-7 (Z,E)-3-(4-acetoxy-3,5-dibromo-phenyl)-2-acetylamino-acrylic acid 
• 300-38-9 3,5-dibromo-L-tyrosine 
• 740808-93-9 trifluoro-acetic acid 2,6-dibromo-4-(5-oxo-2-trifluoromethyl-4,5-dihydro-oxazol-4-ylmethyl)-phenyl ester 
• 495-69-2 Hippuric Acid 

Downstream Products

• 866087-53-8 (R)-3-(3,5-dibromo-4-hydroxy-phenyl)-2-hydroxy-propionic acid 
• 866087-54-9 (R)-3-(3,5-dibromo-4-hydroxy-phenyl)-2-hydroxy-propionic acid methyl ester 
• 1389250-17-2 C₁₈H₁₁Br₂N₃O₂S 
• 1389250-19-4 C₁₉H₁₃Br₂N₃O₂S 
• 1389250-21-8 C₁₉H₁₃Br₂N₃O₃S 
• 1389250-15-0 C₁₀H₇Br₂N₃O₂S 
• 80314-47-2 3-[(S)-3-Bromo-5-(2,6-dibromo-4-{2-methoxycarbonyl-2-[(Z)-methoxyimino]-ethyl}-phenoxy)-1-methoxy-4-oxo-cyclohexa-2,5-dienyl]-2-[(Z)-methoxyimino]-propionic acid methyl ester 
• 80314-45-0 3-(3,5-Dibromo-4-hydroxy-phenyl)-2-[(Z)-methoxyimino]-propionic acid methyl ester 
• 740808-92-8 2-benzyloxyimino-3-(3,5-dibromo-4-hydroxyphenyl)propionic acid 

Relevant articles and documents

-

-

Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets

Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases. The design and synthesis of a focused library based on the psammaplin A core has been carried out to probe the molecular features of this molecule responsible for its activity. By direct in vitro assay of the free thiol generated upon reduction of the dimeric psammaplin scaffold, we have unambiguously demonstrated that 11c functions as a natural prodrug, with the reduced form being highly potent against HDAC1 in vitro (IC50 0.9 nM). Furthermore, we have shown it to have high isoform selectivity, being 360-fold selective for HDAC1 over HDAC6 and more than 1000-fold less potent against HDAC7 and HDAC8. SAR around our focused library revealed a number of features, most notably the oxime functionality to be important to this selectivity. Many of the compounds show significant cytotoxicity in A549, MCF7, and W138 cells, with the SAR of cytotoxicity correlating to HDAC inhibition. Furthermore, compound treatment causes upregulation of histone acetylation but little effect on tubulin acetylation. Finally, we have found no evidence for 11c functioning as a DNMT inhibitor.

CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I) in which: R1, R2, R3, R4 and X are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts as well as the hydrates of the salts, in particular, their physiologically compatible salts with inorganic or organic acids and bases, and those compounds of general formula (I) in which one or more hydrogen atoms are replaced by deuterium. The invention also relates to medicaments containing these compounds, the use thereof, and to methods for producing them.